secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001193125-23-274124
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon Q3 net loss $14.5M; cash $142.1M; ACR-368 shows early clinical activity
-------------------------------------------------------------------------------

- Net loss of $14.5M in Q3 2023 vs $9.2M in Q3 2022; R&D expenses $10.3M, G&A $5.9M.
- Cash and marketable securities $142.1M as of Sept 30, 2023; expected to fund operations into H2 2025.
- ACR-368: initial clinical activity observed in OncoSignature-positive patients across ovarian, endometrial, urothelial cancers; mature data H1 2024.
- ACR-2316 dual WEE1/PKMYT1 inhibitor: IND submission planned Q4 2024; designed for superior single-agent activity via AP3 platform.
- Two posters at AACR-NCI-EORTC conference validate ACR-368 OncoSignature assay with 47-58% ORR in tumor biopsies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000119312523274124/0001193125-23-274124-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000119312523274124/d591379d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-274124

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer